Key result
Ranolazine monotherapy in the absence of concomitant statin use induced generalized myalgia and elevated creatinine kinase levels to 4551 U/L, which resolved upon discontinuation.
Why the study?
Does ranolazine monotherapy cause elevated creatinine kinase and myalgias in the absence of statin usage?
Case Report (n=1)
No
Does ranolazine monotherapy cause elevated creatinine kinase and myalgias in the absence of statin usage?
Ranolazine monotherapy may cause elevated creatinine kinase and myalgias even in the absence of concomitant statin therapy.
Answers are grounded in this paper and cite their sources.
Ranolazine may cause myopathy without statins; hypothesis-generating case report requiring confirmation.
Ranolazine received Food and Drug Administration (FDA) approval in 2006 for the treatment of chronic angina. Ranolazine has previously been linked to the development of statin-induced myopathy, because it also inhibits CYP3A4, which increases serum statin levels. In the absence of concomitant statin therapy, elevated creatinine kinase (CK) and myalgias on ranolazine monotherapy has never been reported.
No takes yet. Share an insight, caveat, or question.
Dein et al. (2018) conducted a case report in Suspected coronary vasospasm (n=1). Ranolazine was evaluated on Creatinine kinase (CK) level. Ranolazine monotherapy in the absence of concomitant statin use induced generalized myalgia and elevated creatinine kinase levels to 4551 U/L, which resolved upon discontinuation.
Synapse has enriched 10 related papers. Consider them for comparative context: